COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01600209
Recruitment Status : Completed
First Posted : May 17, 2012
Last Update Posted : May 13, 2015
Information provided by (Responsible Party):
Exact Sciences Corporation

Brief Summary:
The objective of this study is to confirm the sensitivity and specificity of a stool DNA test for detection of colorectal cancer and pre-cancer.

Condition or disease
Colorectal Neoplasms Digestive System Diseases Colonic Diseases Colorectal Cancer

Detailed Description:
Patients who have recently undergone a colonoscopy that resulted with normal findings will be asked to submit a stool sample (s) (at least 30 days AFTER colonoscopy).

Layout table for study information
Study Type : Observational
Actual Enrollment : 674 participants
Observational Model: Case-Only
Official Title: Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing
Study Start Date : October 2011
Actual Primary Completion Date : August 2012
Actual Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Average risk patients
Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.

Primary Outcome Measures :
  1. Sensitivity and Specificity of the Exact CRC diagnostic screening test. [ Time Frame: 10 months ]
    The primary endpoints are point estimates of the sensitivity of the diagnostic tests for detection of colorectal neoplasms.

Biospecimen Retention:   Samples With DNA
Provide anonymous, clinically characterized specimens for bio-repository for future colorectal cancer-related test development.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients are at average risk of developing colorectal cancer at the time of their colonoscopy and the colonoscopy resulted in normal findings.

Inclusion Criteria:

  • Subject is male or female, 50-84 years of age, inclusive.
  • Subject is at average risk for development of CRC and has undergone a screening colonoscopy with a normal result at least 30 days and no more than 120 days before providing a stool sample for the study. For the purposes of this study, a "normal" colonoscopy result is defined as no polyps of any size detected or removed (including benign, hyperplastic polyps).
  • Subject is able to understand the study procedures, and is able to provide signed consent to participate in the study and authorizes release of relevant protected health information through signing a HIPAA consent.
  • Subject is able and willing to provide stool samples at least 30 days and no more than 120 days after undergoing a colonoscopy that resulted in normal findings, according to the written instructions provided to them.

Exclusion Criteria:

  • Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
  • Subject had any findings on recent or any previous colonoscopy including benign, and/or hyperplastic polyps of any size. (Note: Tissue biopsies that result in no histopathology findings are acceptable.)
  • Subject has a history or recent diagnosis of CRC or adenoma.
  • Subject has a history of aerodigestive tract cancer.
  • Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
  • Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
  • Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:

    • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
    • Greater than or equal to (>=)2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
    • One first-degree relative with CRC diagnosed before the age of 60.
    • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
    • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
    • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01600209

Layout table for location information
United States, Arizona
Desert Sun Clinical Research
Tucson, Arizona, United States, 85710
United States, California
Remek Research
Pomona, California, United States, 91767
Sharp Rees-Stealy
San Diego, California, United States, 92101
Southern California Medical Gastroenterology Group, Inc
Santa Monica, California, United States, 90404
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33173
United States, Georgia
Atlanta Gastroenterology Associates
Marietta, Georgia, United States, 30067
United States, Illinois
Rockford Gastroenterology Associates, LTD.
Rockford, Illinois, United States, 61107
United States, Louisiana
New Orleans Research Institue
Metairie, Louisiana, United States, 70006
United States, Maryland
Columbia Medical Practice
Columbia, Maryland, United States, 21045
United States, Pennsylvania
Main Line Gastroenterology
Perkasie, Pennsylvania, United States, 18944
United States, Texas
Professional Quality Research, Inc.
Austin, Texas, United States, 78705
United States, Utah
Advanced Research Institute
Ogden, Utah, United States, 84405
Advanced Research Institute
Sandy, Utah, United States, 84094
Sponsors and Collaborators
Exact Sciences Corporation
Layout table for investigator information
Study Chair: Graham Lidgard, PhD Chief Scientific Officer
Publications of Results:
Layout table for additonal information
Responsible Party: Exact Sciences Corporation Identifier: NCT01600209    
Other Study ID Numbers: Exact Sciences 2011-N
First Posted: May 17, 2012    Key Record Dates
Last Update Posted: May 13, 2015
Last Verified: May 2015
Keywords provided by Exact Sciences Corporation:
Colorectal Cancer
Colorectal Neoplasm
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Digestive System Diseases
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Intestinal Diseases
Rectal Diseases